Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
Adult
Antibodies, Viral
/ blood
Antigens, Viral
/ immunology
Betacoronavirus
/ immunology
COVID-19
Coronavirus Infections
/ immunology
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Longitudinal Studies
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ immunology
SARS-CoV-2
Saliva
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Journal
Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624
Informations de publication
Date de publication:
08 10 2020
08 10 2020
Historique:
received:
28
08
2020
accepted:
05
10
2020
entrez:
9
10
2020
pubmed:
10
10
2020
medline:
28
10
2020
Statut:
ppublish
Résumé
While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about the antibody response in saliva and its relationship to systemic antibody levels. Here, we profiled by enzyme-linked immunosorbent assays (ELISAs) IgG, IgA and IgM responses to the SARS-CoV-2 spike protein (full length trimer) and its receptor-binding domain (RBD) in serum and saliva of acute and convalescent patients with laboratory-diagnosed COVID-19 ranging from 3-115 days post-symptom onset (PSO), compared to negative controls. Anti-SARS-CoV-2 antibody responses were readily detected in serum and saliva, with peak IgG levels attained by 16-30 days PSO. Longitudinal analysis revealed that anti-SARS-CoV-2 IgA and IgM antibodies rapidly decayed, while IgG antibodies remained relatively stable up to 105 days PSO in both biofluids. Lastly, IgG, IgM and to a lesser extent IgA responses to spike and RBD in the serum positively correlated with matched saliva samples. This study confirms that serum and saliva IgG antibodies to SARS-CoV-2 are maintained in the majority of COVID-19 patients for at least 3 months PSO. IgG responses in saliva may serve as a surrogate measure of systemic immunity to SARS-CoV-2 based on their correlation with serum IgG responses.
Identifiants
pubmed: 33033173
pii: 5/52/eabe5511
doi: 10.1126/sciimmunol.abe5511
pmc: PMC8050884
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020, American Association for the Advancement of Science.
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Lancet. 1987 Jul 11;2(8550):72-5
pubmed: 2885575
J Exp Med. 2007 May 14;204(5):1217-25
pubmed: 17485516
Zentralbl Veterinarmed B. 1994 Oct;41(7-8):467-72
pubmed: 7701859
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5004-9
pubmed: 23476064
J Dent Res. 2020 Jul;99(8):989
pubmed: 32271653
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Cell. 2020 Sep 17;182(6):1663-1673
pubmed: 32946786
Cell. 2019 Jan 24;176(3):610-624.e18
pubmed: 30612739
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Clin Med. 2020 May 15;9(5):
pubmed: 32429101
MAbs. 2010 Jan-Feb;2(1):53-66
pubmed: 20168090
Front Immunol. 2013 Nov 28;4:402
pubmed: 24348474
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Med Microbiol Immunol. 2008 Jun;197(2):205-13
pubmed: 18259775
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Transfusion. 2006 Oct;46(10):1770-7
pubmed: 17002634
J Clin Microbiol. 2015 Sep;53(9):2951-5
pubmed: 26157150
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Lancet Infect Dis. 2002 Jan;2(1):18-24
pubmed: 11892490
Science. 2002 Dec 13;298(5601):2199-202
pubmed: 12481138
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Med (N Y). 2021 Jan 15;2(1):99-112.e7
pubmed: 32838362
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
Nat Commun. 2020 Aug 21;11(1):4198
pubmed: 32826914
Mucosal Immunol. 2016 Jul;9(4):884-93
pubmed: 26509875
Immunity. 2020 May 19;52(5):842-855.e6
pubmed: 32353250
J Biotechnol. 2019 Apr 20;296:32-41
pubmed: 30885656
Clin Oral Investig. 2020 Apr;24(4):1619-1621
pubmed: 32078048
Emerg Infect Dis. 2020 Sep;26(9):2054-2063
pubmed: 32558639
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33067270
J Biotechnol. 2017 Aug 10;255:16-27
pubmed: 28625678
Int J Environ Res Public Health. 2020 Mar 26;17(7):
pubmed: 32224986
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Immunol. 2020 Nov 1;205(9):2342-2350
pubmed: 32887754
G3 (Bethesda). 2020 Sep 2;10(9):3399-3402
pubmed: 32763951
J Exp Med. 2017 Feb;214(2):309-317
pubmed: 28104812
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270